Výsledky vyhledávání - "Andreas Weichselberger"

HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration

Autor: Ursula Schmidt-Erfurth, Pravin U. Dugel, James Warburton, David M. Brown, Hawk, Harrier Study Investigators, Adrian Koh, Glenn J. Jaffe, André Marcelo Vieira Gomes, Andreas Weichselberger, Yuichiro Ogura, Frank G. Holz

Publikováno v: Ophthalmology. 127(1)

Two similarly designed phase 3 trials (HAWK and HARRIER) compared brolucizumab, a single-chain antibody fragment that inhibits vascular endothelial growth factor-A, with aflibercept to treat neovascular age-related macular degeneration (nAMD).Double-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eef7f79ce22f6356f57aca878ae9edd3
https://pubmed.ncbi.nlm.nih.gov/31759510

Zobrazit plný text záznamu

Outcomes following three-line vision loss during treatment of neovascular age-related macular degeneration: subgroup analyses from MARINA and ANCHOR

Autor: Paul Mitchell, Ursula Schmidt-Erfurth, Yehia Hashad, Frank G. Holz, Andreas Weichselberger, Christian Prünte, Paolo Lanzetta, Sebastian Wolf, Jean-François Korobelnik

Publikováno v: British Journal of Ophthalmology. 95:1713-1718

Aim This study aims to assess the impact of continued ranibizumab treatment for neovascular age-related macular degeneration on patients from the MARINA and ANCHOR randomised clinical studies who lost ≥3 lines of best-corrected visual acuity (BCVA)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4161aee9eefa13ba0e86d2015741ff8
https://doi.org/10.1136/bjophthalmol-2011-300471

Zobrazit plný text záznamu

Safety and Efficacy of a Flexible Dosing Regimen of Ranibizumab in Neovascular Age-Related Macular Degeneration: The SUSTAIN Study

Autor: Reinier O. Schlingemann, Juan Peralta Donate, Frank G. Holz, Robyn H. Guymer, Giovanni Staurenghi, Ulrich Kellner, Winfried M Amoaku, Andreas Weichselberger

Publikováno v: Ophthalmology, 118(4), 663-671. Elsevier Inc.

Objective: To evaluate the safety and efficacy of individualized ranibizumab treatment in patients with neovascular age-related macular degeneration. Design: Twelve-month, phase III, multicenter, open-label, single-arm study. Participants: A total of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4928ea1de75fc29121e8ff4a6fa93f9e
https://doi.org/10.1016/j.ophtha.2010.12.019

Zobrazit plný text záznamu

The RESTORE Study

Autor: Paul Mitchell, Ursula Schmidt-Erfurth, Gabriela Burian, Reinier O. Schlingemann, Andreas Weichselberger, Francesco Bandello, Pascale Massin, Florian K. P. Sutter, Christian Simader, Gabriele E. Lang, Ortrud Gerstner

Publikováno v: Ophthalmology. 118(4):615-625

Objective To demonstrate superiority of ranibizumab 0.5 mg monotherapy or combined with laser over laser alone based on mean average change in best-corrected visual acuity (BCVA) over 12 months in diabetic macular edema (DME). Design A 12-month, rand

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4b52dc432a97f5544da3e7544b991b8

Zobrazit plný text záznamu

Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study*)

Autor: Lutz L. Hansen, Simon P. Harding, Justus G. Garweg, Paul Mitchell, Margarita Gekkieva, Pascale Massin, Michael Larsen, Andreas Weichselberger, Dianne Sharp, Sebastian Wolf, Francesco Bandello, U. E. K. Wolf-Schnurrbusch

Publikováno v: Diabetes Care

OBJECTIVE The expression of vascular endothelial growth factor (VEGF) is elevated in diabetic macular edema (DME). Ranibizumab binds to and inhibits multiple VEGF variants. We investigated the safety and efficacy of ranibizumab in DME involving the f

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d0449896e967d6e2c65fda5a2df42a6
http://europepmc.org/articles/PMC2963502

Zobrazit plný text záznamu

Verteporfin therapy in occult with no classic CNV due to AMD: results of the Photodynamic Therapy in Occult-Only Lesions study

Autor: Simon P. Harding, Sebastian Wolf, Gisèle Soubrane, Andreas Weichselberger

Publikováno v: Eye. 23:791-800

To provide further information on verteporfin photodynamic therapy in occult with no classic choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).Verteporfin therapy was administered at baseline and then at months 3,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce0b41bf238e5014e2e5350b115585f4
https://doi.org/10.1038/eye.2008.158

Zobrazit plný text záznamu

Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration

Autor: Rufino Silva, Robin Hamilton, Francesco Bandello, Frank G. Holz, Laura Sararols, Eric H. Souied, Andreas Weichselberger, Dominik Escher, Georges Weissgerber, Michael Larsen, Andreas Wenzel, Pravin U. Dugel, Anne Schmidt

Purpose: To assess the safety and efficacy of different doses of RTH258 applied as single intravitreal administration compared with ranibizumab 0.5 mg in patients with neovascular age-related macular degeneration (AMD). Design: Six-month, phase 1/2,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7063de456c92fe891a52c5ca280128fb

Zobrazit plný text záznamu

Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration: A Randomized Controlled Study

Autor: Frank G, Holz, Pravin U, Dugel, Georges, Weissgerber, Robin, Hamilton, Rufino, Silva, Francesco, Bandello, Michael, Larsen, Andreas, Weichselberger, Andreas, Wenzel, Anne, Schmidt, Dominik, Escher, Laura, Sararols, Eric, Souied

Publikováno v: Ophthalmology. 123(5)

To assess the safety and efficacy of different doses of RTH258 applied as single intravitreal administration compared with ranibizumab 0.5 mg in patients with neovascular age-related macular degeneration (AMD).Six-month, phase 1/2, prospective, multi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::150516b591266b074b49eddd84ea346c
https://pubmed.ncbi.nlm.nih.gov/26906165

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání